Evening administration of long-acting beta-blockers for primary prophylaxis in cirrhosis: an effective strategy.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 21378768)

Published in Am J Gastroenterol on March 01, 2011

Authors

Jayant A Talwalkar

Articles by these authors

Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77

Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36

A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02

Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81

Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69

MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol (2008) 1.69

Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66

AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64

Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58

Noninvasive assessment of liver fibrosis. Hepatology (2011) 1.57

Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53

"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52

Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35

Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33

Abdominal magnetic resonance elastography. Top Magn Reson Imaging (2009) 1.26

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21

Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17

Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14

Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology (2008) 1.11

Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.09

Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07

Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05

Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02

Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology (2006) 1.00

Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol (2010) 0.99

Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99

Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98

Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol (2007) 0.98

Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging (2015) 0.98

Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97

Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.92

Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am (2011) 0.91

Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol (2013) 0.90

Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl (2004) 0.89

Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology (2011) 0.89

Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl (2012) 0.87

Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis (2012) 0.87

Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am (2006) 0.87

Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol (2013) 0.86

Hepatic and splenic stiffness augmentation assessed with MR elastography in an in vivo porcine portal hypertension model. J Magn Reson Imaging (2013) 0.86

Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol (2006) 0.84

Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl (2013) 0.83

Time trends in hospitalization and discharge status for cirrhosis and portal hypertension in the United States. Hepatology (2010) 0.82

Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2007) 0.82

Celiac disease-associated autoimmune cholangitis. Am J Gastroenterol (2002) 0.80

Clinical management of autoimmune biliary diseases. J Autoimmun (2013) 0.80

Cholestatic liver disease. Med Clin North Am (2013) 0.79

One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology (2009) 0.78

Methodologic issues with transfer of ultrasound-based transient elastography into clinical practice. J Hepatol (2007) 0.78

Economic impact of hospitalization for end-stage liver disease. Am J Gastroenterol (2002) 0.78

Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl (2012) 0.78

MR Elastography of Liver Disease: State of the Art. Appl Radiol (2013) 0.77

Acute graft-versus-host disease after liver transplantation. Transplantation (2007) 0.77

Chronic inflammation, liver stiffness, and clinical decision making: an unavoidable partnership. Clin Gastroenterol Hepatol (2012) 0.77

Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep (2013) 0.76

Predicting clinical outcomes with elastography in primary biliary cirrhosis: one step closer? Gastroenterology (2013) 0.76

Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci (2009) 0.76

Functional hepatic imaging and disease recurrence after liver transplantation. Liver Transpl (2006) 0.75

Role of computerized image morphometry for assessing noninvasive methods to detect hepatic fibrosis. Clin Gastroenterol Hepatol (2008) 0.75

Polluting the pathogenesis of primary biliary cirrhosis. Hepatology (2006) 0.75

Markov models in primary biliary cirrhosis. Gastroenterology (2002) 0.75

Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes. Hepatology (2008) 0.75

Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75

Determining the nature and impact of fatigue after liver transplantation. Liver Transpl (2006) 0.75

Recall processes for biliary cytology in primary sclerosing cholangitis. Curr Opin Gastroenterol (2014) 0.75

Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis. Liver Int (2008) 0.75

The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2013) 0.75

Recognizing and preventing death from compensated cirrhosis in the community. Liver Int (2011) 0.75

Quantitative dynamic contrast-enhanced magnetic resonance imaging for assessing treatment response in hepatocellular carcinoma. Gastroenterology (2008) 0.75

Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep (2015) 0.75

A 48-year-old woman with a new diagnosis of autoimmune hepatitis. Clin Gastroenterol Hepatol (2012) 0.75

Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. Am J Manag Care (2016) 0.75